Stoke Therapeutics (STOK) Free Cash Flow (2018 - 2026)

Stoke Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$60.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 146.26% year-over-year to -$60.9 million; the TTM figure through Mar 2026 stood at -$147.5 million (down 312.72% YoY), while the FY2025 annual figure was $45.1 million, up 151.9% from the prior year.
• Free Cash Flow was -$60.9 million for Q1 2026 at Stoke Therapeutics, down from -$30.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $131.7 million in Q1 2025 to a low of -$60.9 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$13.0 million across 5 years, with a median of -$21.9 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow plunged 169.2% in 2023, then soared 635.87% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$25.9 million in 2022, then rose by 19.48% to -$20.9 million in 2023, then slipped by 10.61% to -$23.1 million in 2024, then tumbled by 32.07% to -$30.5 million in 2025, then tumbled by 99.74% to -$60.9 million in 2026.
• The last three Free Cash Flow figures came in at -$60.9 million (Q1 2026), -$30.5 million (Q4 2025), and -$30.8 million (Q3 2025), per Business Quant data.